NGN Capital invests additional $4.6 mln in Zenith Epigenetics
Zenith Epigenetics Corp, a Calgary-based early-stage biotechnology company, has raised $4.6 million from a private placement offering. The source of the funding was an existing investor, U.S. healthcare-focused venture capital firm NGN Capital. NGN also participated with Eastern Capital in a US$8 million financing in March. Zenith, which last year emerged as the result of RVX Therapeutics Inc's spinout from Resverlogix Corp (TSX: RVX), intends to use offering proceeds to fund research and development activities and other business purposes.
23 July 2014•3 mins read
